98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. Published study complements KidneyIntelX clinical utility data published at American Diabetes Association Annual
RNS Number : 1019V Renalytix PLC 08 August 2022 Renalytix plc ("Renalytix" or the "Company") Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX TM with Primary Care Physicians 98% of 401 Primary Care Physicians confirmed
LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 7475Q Renalytix PLC 30 June 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022 LONDON and SALT LAKE CITY , June 30, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and
RNS Number : 8594P Renalytix PLC 23 June 2022 Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 NEW YORK and SALT LAKE CITY , June 23, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022
Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly
RNS Number : 4139O Renalytix PLC 10 June 2022 Renalytix plc ("Renalytix" or the "Company") 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients Late-breaking data presented at American
NEW YORK and SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast
RNS Number : 0740O Renalytix PLC 08 June 2022 Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth
